NCT04761952 is a NA clinical trial of azathioprine in Inflammatory Bowel Diseases, sponsored by Sixth Affiliated Hospital, Sun Yat-sen University.

Who is sponsoring NCT04761952?

NCT04761952 is sponsored by Sixth Affiliated Hospital, Sun Yat-sen University.

What drugs are being tested in NCT04761952?

Interventions in NCT04761952: azathioprine, infliximab, N-3 Polyunsaturated Fatty Acids.

What condition does NCT04761952 study?

NCT04761952 studies Inflammatory Bowel Diseases, Crohn Disease, Polyunsaturated Acid Lipidosis.

Is NCT04761952 still recruiting?

NCT04761952 is currently status unknown. Last updated 21 February 2021.

Last reviewed 2021-02-21 · How we verify

NCT04761952

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's Disease

Status unknown NA Last updated 21 February 2021

What this trial tests

NA trial testing azathioprine in Inflammatory Bowel Diseases in 236 participants. Status unknown.

Timeline

13 February 2021

Primary endpoint
31 December 2022

31 December 2023

Quick facts

Lead sponsor	Sixth Affiliated Hospital, Sun Yat-sen University
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	236
Start date	13 February 2021
Primary completion	31 December 2022
Estimated completion	31 December 2023

Drugs / interventions tested

azathioprine (AZATHIOPRINE) — full drug profile →
infliximab (infliximab) — full drug profile →
N-3 Polyunsaturated Fatty Acids — full drug profile →

Conditions studied

Inflammatory Bowel Diseases — all drugs for Inflammatory Bowel Diseases →
Crohn Disease — all drugs for Crohn Disease →
Polyunsaturated Acid Lipidosis — all drugs for Polyunsaturated Acid Lipidosis →

Sponsor

Sixth Affiliated Hospital, Sun Yat-sen University

Who can join

Adults 18 to 80, any sex, with Inflammatory Bowel Diseases or Crohn Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Crohn's disease (CD) is a chronic recurrent intestinal inflammation involving the whole digestive tract, with high disability rate, high surgical rate and high recurrent rate postoperatively. Preventing postoperative recurrence in CD patients is an important clinical problem needed urgent intervention. Azathioprine (AZA) and infliximab (IFX) effectively prevent postoperative recurrence in CD patients, but the postoperative recurrence rate is still as high as 41%. Oral supplement of n-3 polyunsaturated fatty acids (n-3 PUFA) owns the advantages of high compliance and low economic cost. We aim to evaluate the effect of routine treatment (AZA/IFX) combined with long-term dietary n-3PUFA on the prevention and treatment of postoperative recurrence of CD, which help optimize the treatment strategy for the prevention of postoperative recurrence.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of azathioprine

Trials testing the same drug.

NCT04160325 — Effect of the Exclusive Enteral Nutrition Combined With Azathioprine for Remission of Crohn's Diseases After Surgery · NA · unknown
NCT03229746 — Reposition of Second Line Treatment in Chronic Immune Thrombocytopenia · Phase 4 · completed

Other recruiting trials for Inflammatory Bowel Diseases

Currently open trials in the same condition.

NCT07520747 — A Database Study of Disease, Treatment Patterns and Healthcare Use in Children With Inflammatory Bowel Diseases in Korea · recruiting
NCT07349472 — Pentoxifylline in Patients With Ulcerative Colitis · Phase 2 · recruiting
NCT07033208 — Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance · NA · recruiting
NCT06842316 — Effects of Phytocannabinoids on Immune Response and Autophagy During Chronic Immune-mediated Inflammatory Diseases · recruiting
NCT06453317 — Comparison of Ustekinumab, Infliximab and Combination Therapy in Moderately to Severely Active Ulcerative Colitis · Phase 2 · recruiting

Other Sixth Affiliated Hospital, Sun Yat-sen University trials

Trials by the same sponsor.

NCT07538284 — MInimizing Delirium With Nasal Dexmedetomidine-InducEd Sleep (MIDDIES) · Phase 2, PHASE3 · not yet recruiting
NCT07176182 — Clinical Trial of Neoadjuvant mFOLFOX Plus Alvenor for LARC Patients With High YWHAB Expression · Phase 2 · not yet recruiting
NCT07510191 — TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal Response · Phase 4 · recruiting
NCT07344428 — Efficacy and Safety of CDED With Anti-TNF-α Biologics in Crohn's Disease: A Randomized Trial · NA · not yet recruiting
NCT07328958 — Effect of Titrated Administration of Ciprofol on Perioperative Hypotension in Elderly Patients Undergoing Laparoscopic A · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04761952 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sixth Affiliated Hospital, Sun Yat-sen University
Last refreshed: 21 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04761952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing